Growth hormone and prolactin stimulation by Madopar in Parkinson's disease

A. Martinez-Campos, P. Giovannini, E. Parati, A. Novelli, T. Caraceni, E. E. Müller

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Madopar, a combination of levodopa with benserazide, induced an inconsistent rise in plasma growth hormone in unmedicated patients with Parkinson's disease and in controls, and a greater growth hormone rise in Parkinsonian subjects on chronic Madopar therapy. In subjects on chronic therapy with levodopa and carbidopa (Sinemet), the growth hormone releasing effect of Madopar was blunted. Madopar increased plasma prolactin (PRL) in controls, unmedicated patients and patients on Madopar therapy while in patients on Sinemet therapy the PRL-releasing effect of Madopar was strikingly reduced. Since these data were interpreted as due to a defective dopamine tone in the hypothalamus of Parkinsonian subjects on Madopar but not Sinemet therapy, a direct dopamine receptor agonist, lisuride was administered. Lisuride, however, elicited a blunted growth hormone response both in patients on Madopar and Sinemet therapy, without revealing a state of supersensitivity of dopamine receptors for growth hormone control in Parkinsonian subjects on Madopar therapy. No differences was present in the PRL-lowering effect of lisuride in the different experimental groups. These findings suggest that: (1) hypothalamic dopamine function is impaired in Parkinsonian subjects on Madopar therapy, preserved in unmedicated patients and enhanced in patients on Sinemet therapy; (2) the endocrine effects observed in Parkinsonian subjects on chronic Madopar therapy may be due to some penetration of benserazide across the blood brain barrier in the region of the hypothalamus; (3) since Madopar and Sinemet are in essence equally effective antiparkinsonian remedies, penetration of benserazide does not occur across the blood brain barrier surrounding the nigrostriatal system.

Original languageEnglish
Pages (from-to)1116-1123
Number of pages8
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume44
Issue number12
Publication statusPublished - 1981

Fingerprint

Prolactin
Growth Hormone
Parkinson Disease
Lisuride
Benserazide
Therapeutics
Blood-Brain Barrier
levodopa drug combination benserazide
Hypothalamus
Dopamine
Antiparkinson Agents
Dopamine Agonists
Dopamine Receptors
levodopa drug combination carbidopa

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

Martinez-Campos, A., Giovannini, P., Parati, E., Novelli, A., Caraceni, T., & Müller, E. E. (1981). Growth hormone and prolactin stimulation by Madopar in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 44(12), 1116-1123.

Growth hormone and prolactin stimulation by Madopar in Parkinson's disease. / Martinez-Campos, A.; Giovannini, P.; Parati, E.; Novelli, A.; Caraceni, T.; Müller, E. E.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 44, No. 12, 1981, p. 1116-1123.

Research output: Contribution to journalArticle

Martinez-Campos, A, Giovannini, P, Parati, E, Novelli, A, Caraceni, T & Müller, EE 1981, 'Growth hormone and prolactin stimulation by Madopar in Parkinson's disease', Journal of Neurology, Neurosurgery and Psychiatry, vol. 44, no. 12, pp. 1116-1123.
Martinez-Campos A, Giovannini P, Parati E, Novelli A, Caraceni T, Müller EE. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 1981;44(12):1116-1123.
Martinez-Campos, A. ; Giovannini, P. ; Parati, E. ; Novelli, A. ; Caraceni, T. ; Müller, E. E. / Growth hormone and prolactin stimulation by Madopar in Parkinson's disease. In: Journal of Neurology, Neurosurgery and Psychiatry. 1981 ; Vol. 44, No. 12. pp. 1116-1123.
@article{8f830093013e4c88ba0f926be0a66491,
title = "Growth hormone and prolactin stimulation by Madopar in Parkinson's disease",
abstract = "Madopar, a combination of levodopa with benserazide, induced an inconsistent rise in plasma growth hormone in unmedicated patients with Parkinson's disease and in controls, and a greater growth hormone rise in Parkinsonian subjects on chronic Madopar therapy. In subjects on chronic therapy with levodopa and carbidopa (Sinemet), the growth hormone releasing effect of Madopar was blunted. Madopar increased plasma prolactin (PRL) in controls, unmedicated patients and patients on Madopar therapy while in patients on Sinemet therapy the PRL-releasing effect of Madopar was strikingly reduced. Since these data were interpreted as due to a defective dopamine tone in the hypothalamus of Parkinsonian subjects on Madopar but not Sinemet therapy, a direct dopamine receptor agonist, lisuride was administered. Lisuride, however, elicited a blunted growth hormone response both in patients on Madopar and Sinemet therapy, without revealing a state of supersensitivity of dopamine receptors for growth hormone control in Parkinsonian subjects on Madopar therapy. No differences was present in the PRL-lowering effect of lisuride in the different experimental groups. These findings suggest that: (1) hypothalamic dopamine function is impaired in Parkinsonian subjects on Madopar therapy, preserved in unmedicated patients and enhanced in patients on Sinemet therapy; (2) the endocrine effects observed in Parkinsonian subjects on chronic Madopar therapy may be due to some penetration of benserazide across the blood brain barrier in the region of the hypothalamus; (3) since Madopar and Sinemet are in essence equally effective antiparkinsonian remedies, penetration of benserazide does not occur across the blood brain barrier surrounding the nigrostriatal system.",
author = "A. Martinez-Campos and P. Giovannini and E. Parati and A. Novelli and T. Caraceni and M{\"u}ller, {E. E.}",
year = "1981",
language = "English",
volume = "44",
pages = "1116--1123",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "12",

}

TY - JOUR

T1 - Growth hormone and prolactin stimulation by Madopar in Parkinson's disease

AU - Martinez-Campos, A.

AU - Giovannini, P.

AU - Parati, E.

AU - Novelli, A.

AU - Caraceni, T.

AU - Müller, E. E.

PY - 1981

Y1 - 1981

N2 - Madopar, a combination of levodopa with benserazide, induced an inconsistent rise in plasma growth hormone in unmedicated patients with Parkinson's disease and in controls, and a greater growth hormone rise in Parkinsonian subjects on chronic Madopar therapy. In subjects on chronic therapy with levodopa and carbidopa (Sinemet), the growth hormone releasing effect of Madopar was blunted. Madopar increased plasma prolactin (PRL) in controls, unmedicated patients and patients on Madopar therapy while in patients on Sinemet therapy the PRL-releasing effect of Madopar was strikingly reduced. Since these data were interpreted as due to a defective dopamine tone in the hypothalamus of Parkinsonian subjects on Madopar but not Sinemet therapy, a direct dopamine receptor agonist, lisuride was administered. Lisuride, however, elicited a blunted growth hormone response both in patients on Madopar and Sinemet therapy, without revealing a state of supersensitivity of dopamine receptors for growth hormone control in Parkinsonian subjects on Madopar therapy. No differences was present in the PRL-lowering effect of lisuride in the different experimental groups. These findings suggest that: (1) hypothalamic dopamine function is impaired in Parkinsonian subjects on Madopar therapy, preserved in unmedicated patients and enhanced in patients on Sinemet therapy; (2) the endocrine effects observed in Parkinsonian subjects on chronic Madopar therapy may be due to some penetration of benserazide across the blood brain barrier in the region of the hypothalamus; (3) since Madopar and Sinemet are in essence equally effective antiparkinsonian remedies, penetration of benserazide does not occur across the blood brain barrier surrounding the nigrostriatal system.

AB - Madopar, a combination of levodopa with benserazide, induced an inconsistent rise in plasma growth hormone in unmedicated patients with Parkinson's disease and in controls, and a greater growth hormone rise in Parkinsonian subjects on chronic Madopar therapy. In subjects on chronic therapy with levodopa and carbidopa (Sinemet), the growth hormone releasing effect of Madopar was blunted. Madopar increased plasma prolactin (PRL) in controls, unmedicated patients and patients on Madopar therapy while in patients on Sinemet therapy the PRL-releasing effect of Madopar was strikingly reduced. Since these data were interpreted as due to a defective dopamine tone in the hypothalamus of Parkinsonian subjects on Madopar but not Sinemet therapy, a direct dopamine receptor agonist, lisuride was administered. Lisuride, however, elicited a blunted growth hormone response both in patients on Madopar and Sinemet therapy, without revealing a state of supersensitivity of dopamine receptors for growth hormone control in Parkinsonian subjects on Madopar therapy. No differences was present in the PRL-lowering effect of lisuride in the different experimental groups. These findings suggest that: (1) hypothalamic dopamine function is impaired in Parkinsonian subjects on Madopar therapy, preserved in unmedicated patients and enhanced in patients on Sinemet therapy; (2) the endocrine effects observed in Parkinsonian subjects on chronic Madopar therapy may be due to some penetration of benserazide across the blood brain barrier in the region of the hypothalamus; (3) since Madopar and Sinemet are in essence equally effective antiparkinsonian remedies, penetration of benserazide does not occur across the blood brain barrier surrounding the nigrostriatal system.

UR - http://www.scopus.com/inward/record.url?scp=0019851649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019851649&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 1116

EP - 1123

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 12

ER -